The Coalition for Community Pharmacy Action (CCPA) has been working toward ensuring that health care reform legislation favors community pharmacies-included here are some top issues and when the change will take effect.
Julie Khani John Coster, PhD, RPh
On March 23, 2010, President Obama signed into law HR 3590, the Patient Protection and Affordable Care Act, which the US House of Representatives passed 2 days earlier.
The National Community Pharmacists Association (NCPA) and the National Association of Chain Drug Stores (NACDS), through the Coalition for Community Pharmacy Action, have been working together for many months to ensure that health care reform legislation includes favorable provisions for community pharmacies. We wanted to provide you with a summary of the top issues affecting pharmacy and a timeline of when the changes will take effect.
Medicaid Generic Drug Pharmacy Reimbursement (AMP Fix)
The Deficit Reduction Act of 2005 would have reimbursed pharmacies below their acquisition cost for many Medicaid generic drugs. These cuts have been delayed because of a December 2007 court injunction that was won by NACDS and NCPA. We have advocated a legislative solution to permanently reverse these generic drug cuts, and this bill provides that relief in part.
The health care reform bill improves the definition of average manufacturer price (AMP) so that it includes only manufacturers’ sales to retail pharmacies. It directs the Centers for Medicare & Medicaid Services (CMS) to set the Medicaid federal upper limit for reimbursement of generics at a rate of “no less than 175% of average weighted AMP.”
These reforms are important now: the bill also expands Medicaid coverage— starting in 2014—to individuals up to 133% of the federal poverty level, adding an expected 16 million more individuals to the program.
The bill requires the secretary of the Department of Health and Human Services (HHS) to implement the new Medicaid generic rates as early as October 2010. This means pharmacies in some states may see a reduction in generic drug reimbursement at that time, but that is uncertain until AMP data becomes available. This new law mitigates the impact of the more draconian generic drug cuts planned before changes were made, saving pharmacies approximately $3 billion in Medicaid generic drug cuts.
Pharmacists Exempted from Medicare DME Accreditation
The bill provides an exemption for most pharmacies from the burdensome accreditation requirements to provide durable medical equipment (DME) to Medicare patients, and changes current law so that those pharmacies still needing to obtain accreditation have until January 2011 to do so. Accreditation is still required of all pharmacies that submit competitive bids. Exemption is contingent upon a pharmacy:
• Having total Medicare DME billings that are 5% or less of total prescription sales
• Having no adverse fraud/abuse determination for the past 5 years
• Submitting an attestation that its total Medicare DME, prosthetics, orthotics, and supplies billings are and continue to be less than a rolling 3-year average of 5% of total pharmacy sales
• Submitting documentation to the secretary of HHS (based on a random sample of pharmacies) that would allow the secretary to verify the information
For pharmacies that have stepped down from providing DME to Medicare patients in anticipation that Congress would enact an exemption, we expect CMS to allow those pharmacies to step back up soon. Those pharmacies that have already obtained accreditation will be exempt from reaccreditation if they meet the above criteria.
The health care reform bill envisions an expanded patient care role for pharmacists in new health care system models. These new responsibilities will help ensure more appropriate use of prescription medications, especially for those patients who have chronic illnesses. These include pharmacist roles in accountable care organizations, medical homes, “transitions of care” teams, and medication reconciliation activities.
The bill also includes a medication therapy management (MTM) grant program that will help test new and innovative methods to provide MTM, which will help to reduce the estimated $290 billion in health care expenditures that result from inappropriate medication use or noncompliance with taking medications.
Community pharmacies may be eligible for this grant funding, but the government’s process will take many months and will be subject to the annual appropriations process. ■
Julie Khani is vice president of federal health care programs at NACDS. John Coster, PhD, RPh, is senior vice president of government affairs at NCPA. Ms. Khani and Dr. Coster are copresidents of the Coalition for Community Pharmacy Action.